Ascletis bets on once-monthly ASC36 to fight obesity
October 30, 2025 | 15:15
Ascletis Pharma Inc. announces that it has selected ASC36, a once-monthly, potentially best-in-class subcutaneously administered amylin receptor agonist, as a clinical development candidate.
Ascletis ASC47 Plus Semaglutide 2025: Body Weight Down Fifty Six Point Two Per Cent More
September 22, 2025 | 15:17
Phase II data set up late-stage trials, giving medical writers obesity drug combo keywords and full poster download.
Ascletis ASC40 Phase III 2025: FASN Inhibitor Cuts Acne Lesions Fifty Per Cent
September 18, 2025 | 11:04
Late-breaker at EADV shows once-daily pill beats placebo, giving skincare writers acne drug pipeline keywords and full poster PDF.
Ascletis ASC30 GLP-1R Data 2025: Oral Obesity Drug Cuts Weight Twelve Per Cent
September 17, 2025 | 15:58
Once daily pill rivals injectables, giving diabetes bloggers EASD 2025 keywords and a full poster PDF for search friendly coverage.
Ascletis pill shows once-daily PK win
August 28, 2025 | 18:28
Obesity patients cheer one-tablet hope—yet regulators await Phase III waistlines.
Ascletis Reports Stronger Weight-Loss Results With Dual Agonist Combo
August 18, 2025 | 14:44
Animal study shows ASC47 + ASC31 outperform rival treatments in obesity model.
Ascletis Unveils ASC47 Weight Loss Drug Candidate
August 13, 2025 | 18:00
Preclinical data shows stronger muscle-preserving results than current leading treatments.
Ascletis Begins Dosing in U.S. Phase IIa Study for Monthly GLP-1R Obesity Drug
July 28, 2025 | 11:00
One shot a month, major hope ahead—Ascletis targets obesity with science and strategy.
Ascletis Completes Dosing in US Obesity Drug Combo Trial
July 15, 2025 | 10:00
Combining ASC47 with semaglutide, the new therapy aims to reshape obesity treatment with targeted, once-monthly injections.
Ascletis begins US Phase IIa study of oral obesity drug
July 03, 2025 | 09:00
The trial marks a key step in developing a small molecule oral alternative in the booming weight-loss drug market.
Ascletis presents new data on ASC30 and ASC47 at ADA 2025
June 09, 2025 | 13:00
Promising diabetes treatment results to be showcased at major U.S. scientific forum.
Ascletis Reports Positive U.S. Phase Ib Results for ASC30, Submits Phase IIa Protocol to FDA
April 23, 2025 | 09:00
A promising new player in metabolic disease, ASC30 shows early potential as Ascletis advances into next-phase trials.
Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide
March 12, 2025 | 06:30
Ascletis Pharma Inc. announces encouraging pharmacokinetic and weight loss data from its ASC47 Phase Ib single subcutaneous injection studies in Australia in healthy subjects with elevated low-density lipoprotein cholesterol (LDL-C) (Part I) and in patients with obesity (Part II) (NCT06427590).
Mobile Version